MedPath

Pyrazinamide

PYRAZINAMIDE TABLETS USP, 500 mg

Approved
Approval ID

ecee3128-a47f-4ced-a1db-4f58c5f3e9c6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 14, 2022

Manufacturers
FDA

Akorn

DUNS: 117693100

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Pyrazinamide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code61748-012
Application NumberANDA081319
Product Classification
M
Marketing Category
C73584
G
Generic Name
Pyrazinamide
Product Specifications
Route of AdministrationORAL
Effective DateJuly 14, 2022
FDA Product Classification

INGREDIENTS (6)

PYRAZINAMIDEActive
Quantity: 500 mg in 1 1
Code: 2KNI5N06TI
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
DIBASIC CALCIUM PHOSPHATE DIHYDRATEInactive
Code: O7TSZ97GEP
Classification: IACT
STEARIC ACIDInactive
Code: 4ELV7Z65AP
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pyrazinamide - FDA Drug Approval Details